Acute Respiratory Distress Syndrome Clinical Trial
Official title:
Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE
During the past two decades, there current concept has evolved significantly that
ventilator-induced lung injury (VILI) may not only impose a direct mechanical stress and
subsequent injury to the lungs, but may also induce local as well as systemic inflammation
responses, generally referred as biotrauma.1 Patients with ARDS often die of severe systemic
inflammatory response syndrome (SIRS) and multiorgan dysfunction2 rather than refractory
hypoxemia. Ranieri et al found that patients with less severe ARDS, i.e., a lung injury
score of 2.5 or less, receiving ventilation with lung protective strategy involving low
tidal volume (7.5 mL/kg PBW) and high PEEP could attenuate the pulmonary and systemic
cytokine response compared with conventional ventilation with high tidal volume.3 Stuber et
al found an increase in pro-inflammatory cytokines in the lung and plasma of patients with
ARDS within 1 hour after switching the patients from a protective to non-protective
ventilator strategy.4 The receptor for advanced glycation end-products (RAGE) was recently
identified as a marker of injury to the alveolar type I epithelial cells5. Clinical studies
showed that the plasma level of RAGE was associated with severity of lung injury and
clinical outcome, and low tidal volume strategy ventilation accelerated the decline in
plasma RAGE levels. These results suggest plasma RAGE level might be a reliable biomarker of
alveolar epithelial injury in acute lung injury and may associated with ventilator induced
lung injury6. Although, current approach to mechanical ventilation of a patient with ARDS
emphasizes the use of lower tidal volumes with lower plateau pressures to avoid causing lung
overdistension and ventilator associated lung injury (VILI)7; however, in the real world,
some studies showed that strictly reduction of tidal volume to 6ml/kg PBW was modest in
modern time, and was noticed only in patients with greater lung injury scores8. The benefit
of VT strictly reduction to 6ml/kgPBW and its effect on VILI in patients with less severe
ARDS whose Pplat are already below 30 cmH2O are controversy9. One of the possible solutions
is to look at the biomarkers of injury to alveolar epithelial cells. Of these potentially
promising markers, the receptor for advanced glycation end-product (RAGE) is of great
interest.
We hypothesize that a strategy with strict low tidal volume in less severe ARDS and ALI
patients with good compliance may be beneficial to this patient population. Therefore, we
wish to propose a prospective single-center study to investigate the effect of mechanical
ventilation strategy on the plasma level of RAGE in patients with less severe ARDS and acute
lung injury.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All intubated and mechanically ventilated patients who meet the criteria of American-European Consensus Conference (AECC) criteria for ALI/ ARDS: Acute onset of illness Bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema PaO2/FiO2 <= 300 (corrected for altitude): (P/F <300 for ALI and P/F <200 for ARDS) No clinical evidence of left atrial hypertension Exclusion Criteria: - 1. Age <18 years 2. Enrolled in other clinical trials 3. Had confirmed alternative diagnoses that would have different clinical course than ARDS/ALI, e.g., diffuse alveolar hemorrhage, vasculitis, interstitial pneumonitis, etc. 4. Congestive heart failure related pulmonary edema 5. Acute myocardial infarction 6. Pregnancy 7. Patients with definite contraindication to the use of low-tidal volume ventilation, e.g., increased intracranial pressure, tricyclic antidepressant overdose, etc. 8. The patient who meets inclusion criteria initially but rapidly improved within 24 hours of diagnosis of ARDS/ALI |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the effect of mechanical ventilation strategy on the plasma level of RAGE in patients with less severe ARDS and acute lung injury. | 7 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |